Trinity Biotech (Nasdaq:TRIB) today announced the next stage of its transformation plan as it looks to bring a CGM to market.

Trinity Biotech, a commercial-stage biotech company focused on human diagnostics and diabetes management solutions, including wearable biosensors, has appointed Barclays Capital as its exclusive finan ...

With substantial progress in developing its differentiated and innovative CGM and its significant market potential, Trinity Biotech’s board and management have determined that CGM technology and ...

Trinity Biotech (TRIB) has obtained an additional $4M in debt financing from its primary lender, Perceptive Advisors. The additional liquidity ...

StockNews.com cut shares of Trinity Biotech (NASDAQ:TRIB – Free Report) from a hold rating to a sell rating in a research report released on Thursday. Trinity Biotech Stock Up 1.6 % Shares of TRIB ...

In other recent news, Trinity Biotech reported a 3% year-on-year revenue growth in its third quarter of 2024, amounting to $15.2 million. Despite a post-tax net loss of $4.8 million, the company ...

Research analysts at StockNews.com assumed coverage on shares of Trinity Biotech (NASDAQ:TRIB – Get Free Report) in a report released on Wednesday. The firm set a “hold” rating on the stock. Trinity ...

Trinity Biotech PLC (TRIB) reports a 3% revenue increase and outlines strategic initiatives for future growth and profitability. Trinity Biotech PLC (TRIB) reports a 14% revenue increase with ...

(RTTNews) - Trinity Biotech plc (TRIB), a biotechnology company focused on diabetes management, on Thursday announced notable advances in its pre-pivotal trial for its next-generation continuous ...